[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603065":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":12,"responsibleParty":33,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":15,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Tongji Hospital","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Electronic Patient-Reported Outcome Monitoring","Participants complete the MDASI-LC and EQ-5D questionnaires electronically on a weekly basis during CRT and for 12 weeks after CRT. The data are used to evaluate symptom burden, symptom clusters, and symptom trajectories.",[13],{"facility":14,"status":15,"city":16,"state":17,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","430030","China","CN",{"type":22,"coordinates":23},"Point",[24,25],114.26667,30.58333,{"lat":25,"lon":24},[28],{"name":29,"role":30,"phone":31,"phoneExt":7,"email":32},"Qian Chu, MD, PhD","CONTACT","027-69378806","qchu@hust.edu.cn",{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Qian Chu","Professor","100603065","symptoms-burden-in-lung-cancer-patients-undergoing-definitive-chemoradiotherapy-insights-from-electronic-patient-reported-outcomes-100603065",false,"NCT07131670","Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","A Prospective Observational Study on Symptom Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","ePRO-LC-CRT","Inclusion Criteria:\n\n* Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC\n* Age ≥ 18 years\n* Receiving definitive chemoradiotherapy\n* Able and willing to complete electronic questionnaires\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Severe comorbidities (heart, liver, kidney)\n* Psychiatric illness or cognitive impairment\n* Prior chest or mediastinal radiotherapy","ALL","18 Years",{"count":48,"type":49},100,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.",[53,54,55],"Lung Cancer","Chemoradiotherapy","Patient-Reported Outcomes (PRO)",[57,58,59,60,53,61],"Symptom Burden","Symptom Clusters","Electronic Patient-Reported Outcomes","MDASI-LC","EQ-5D","2025-08-12",{"date":64,"type":65},"2025-08-20","ACTUAL",{"date":67,"type":65},"2024-06-01",{"date":69,"type":49},"2026-03-31",{"name":35,"class":6},1]